09921880

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX,

09921880

ENERGY, INSPEC

NEWS EXPRESS	January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:06:25 ON 30 JAN 2003

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:06:52 ON 30 JAN 2003

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5
DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=> s c.....c/sqsp
L1 168545 C.....C/SQSP

=> l1 and sql<=210

09921880

L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and sql<=210
       4885277 SQL<=210
L2   60610 L1 AND SQL<=210

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   45.92   46.13

FILE 'BIOSIS' ENTERED AT 11:29:46 ON 30 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:29:46 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:29:46 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:29:46 ON 30 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:29:46 ON 30 JAN 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 11:29:46 ON 30 JAN 2003
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:29:46 ON 30 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s l2 and (factor or thrombosis or vascular or thrombotic)
TOO MANY TERMS FOR FILE CROSSOVER IN L2
There are limits on the size of an answer set being crossed over from
one file to another. Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> s l2 and (factor)
TOO MANY TERMS FOR FILE CROSSOVER IN L2
There are limits on the size of an answer set being crossed over from
one file to another. Enter HELP CROSSOVER at an arrow prompt (=>)
for specific information.

=> FIL REGISTRY
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   9.22   55.35

FILE 'REGISTRY' ENTERED AT 11:32:16 ON 30 JAN 2003

09921880

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5
DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s cwtwetc/sqsp
L3 14 CWTWETC/SQSP

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 26.90 82.25

FILE 'BIOSIS' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'MEDLINE' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:33:06 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'EMBASE' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'SCISEARCH' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'PCTFULL' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'USPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'USPAT2' ENTERED AT 11:33:06 ON 30 JAN 2003

FILE 'EUROPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003

=> s l3
'SQSP' IS NOT A VALID FIELD CODE

09921880

'SQSP' IS NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L4 3 L3

=> d l4 py pn au ti so ab

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
PY 2001
AU Roberge, Martin; Santell, Lydia; Dennis, Mark S.; Eigenbrot, Charles; Dwyer, Mary A.; Lazarus, Robert A.
TI A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors
SO Biochemistry (2001), 40(32), 9522-9531
CODEN: BICHAW; ISSN: 0006-2960
AB A new inhibitory peptide binding exosite on the protease domain of coagulation Factor VIIa (FVIIa) has been identified. A novel series of peptide inhibitors of FVIIa, termed the "A-series" peptides, identified from peptide phage libraries and exemplified by peptide A-183, specifically bind at a site that is distinct from both the active site and the exosite of another recently described peptide inhibitor of FVIIa, E-76. Peptide A-183 prolonged TF-dependent clotting in human, but not rabbit plasma. Thus, a panel of human FVIIa mutants, contg. 70 of the 76 rabbit sequence differences in the protease domain, localized the binding site to residues in the 60s loop and the C-terminus. The location of the exosite was refined by a series of FVIIa alanine mutants, which showed that proximal residues Trp 61 and Leu 251 were crit. for binding. Kinetic and equil. binding consts. for zymogen FVII, FVIIa and TF.cntdot.FVIIa were detd. using immobilized N-terminal biotinylated A-183 by surface plasmon resonance. No peptide binding to nine other human serine proteases was obsd. Key residues on the peptide were detd. from binding to FVIIa and inhibition of FX activation using a series of alanine mutants of A-183 fused to the Z domain of protein A. Anal. of the mutagenesis data is presented in the context of a crystal structure of A-183 in complex with a version of zymogen FVII. The shape and proximity of this exosite to the active site may lend itself towards the design of new anticoagulants that inhibit FVIIa.

=> d l4 py pn au ti so ab 2-3

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
PY 2001
AU Dennis, Mark S.; Roberge, Martin; Quan, Cliff; Lazarus, Robert A.
TI Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa
SO Biochemistry (2001), 40(32), 9513-9521
CODEN: BICHAW; ISSN: 0006-2960
AB A new series of peptide inhibitors of human Factor VIIa (FVIIa) has been identified and affinity matured from naive and partially randomized peptide phage libraries selected against the immobilized tissue factor.cntdot.Factor VIIa (TF.cntdot.FVIIa) complex. These "A-series" peptides contain a single disulfide bond and a 13-residue minimal core required for maximal affinity. They are exemplified by peptide A-183 (EEWEVLCWTWETCER), which binds at a newly identified exosite on the FVIIa protease domain, described in the accompanying report [Roberge, M., Santell, L., Dennis , M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A. (2001) Biochem. 40, XXXXX-XXXXX]. A-183 was obtained from a trypsin digest of A-100-Z, a recombinant protein comprising A-183 and the Z domain of protein A. Surprisingly, A-183 was a very potent inhibitor of TF.cntdot.FVIIa, inhibiting activation of Factor X (FX) and Factor IX and

amidolytic activity of Chromozym t-PA with IC50 values of 1.6 .+-. 1.2, 3.5 .+-. 0.3, and 8.5 .+-. 3.5 nM, resp. Kinetic anal. revealed that A-183 was a partial (hyperbolic) mixed-type inhibitor of FX activation having a Ki of 200 pM as well as a partial competitive inhibitor of amidolytic activity. The A-series peptides were also specific and potent inhibitors of TF-dependent clotting as measured in a prothrombin time (PT) clotting assay and had no effect on the TF-independent activated partial thromboplastin time. At satg. concns. of peptide, the maximal extent by which A-183 and A-100-Z inhibited the rate of FX activation was 78 .+-. 3 and 89 .+-. 6%, resp. The degree of inhibition of the rate of FX activation correlated with a max. fold prolongation in the PT assay of 1.8-fold for A-183 and 3.3-fold for A-100-Z. The A-series peptides represent a new class of peptide exosite inhibitors that are capable of attenuating, rather than completely inhibiting, the activity of TF.cntdot.FVIIa, potentially leading to anticoagulants with an increased therapeutic window.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
PY 2001
2002

PATENT NO.	KIND	DATE
PI WO 2001010892	A2	20010215
EP 1203014	A2	20020508

IN Dennis, Mark S.
TI Factor VIIa antagonists for diagnostic or therapeutic use
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
AB This invention provides novel compds. which prevent or block a FVIIa mediated or assocd. process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compds. of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the assocn. of FVII or FVIIa with a peptide compd. of the present invention. The invention also provides pharmaceutical compns. comprising the novel compds. as well as their use in diagnostic, therapeutic, and prophylactic methods.

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.86	100.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

FILE 'REGISTRY' ENTERED AT 11:35:06 ON 30 JAN 2003

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

09921880

DICTIONARY FILE UPDATES: 28 JAN 2003 HIGHEST RN 482573-45-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

```
=> s l1 and sql<=20
      1496100 SQL<=20
L5       4615 L1 AND SQL<=20

=> s l1 and sql<=10
       398043 SQL<=10
L6       1711 L1 AND SQL<=10

=> FIL BIOSIS MEDLINE CAPLUS EMBASE SCISEARCH PCTFULL USPATFULL USPAT2 EUROPATFULL
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               9.24     109.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -1.95

FILE 'BIOSIS' ENTERED AT 11:36:13 ON 30 JAN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 11:36:13 ON 30 JAN 2003

FILE 'CAPLUS' ENTERED AT 11:36:13 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:36:13 ON 30 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:36:13 ON 30 JAN 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'PCTFULL' ENTERED AT 11:36:13 ON 30 JAN 2003
COPYRIGHT (C) 2003 Univentio

FILE 'USPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:36:13 ON 30 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=> s l5
```

09921880

'20' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
5 FILES SEARCHED...
'20' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
'20' NOT A VALID FIELD CODE
'SQSP' IS NOT A VALID FIELD CODE
L7 2997 L5

=> s l7 and (factor or thrombosis)
L8 752 L7 AND (FACTOR OR THROMBOSIS)

=> s l7 and (factor (w) VII)
L9 18 L7 AND (FACTOR (W) VII)

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10 18 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l7 and ((factor (w) VII) or FVII or FX or X)
7 FILES SEARCHED...
L11 530 L7 AND ((FACTOR (W) VII) OR FVII OR FX OR X)

=> s l7 and ((factor (w) VII) or FVII or FX)
L12 19 L7 AND ((FACTOR (W) VII) OR FVII OR FX)

=> s l12 and py<=2000
1 FILES SEARCHED...
4 FILES SEARCHED...
L13 13 L12 AND PY<=2000

=> d l13 1-13 py pn au ti so ab

L13 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS
PY **1997**
AU Orning, Lars; Stephens, Ross W.; Petersen, Lizette B.; Hamers, Maria J.A.G.; Stormorken, Helge; Sakariassen, Kjell S.
TI A peptide sequence from the EGF-2 like domain of **FVII** inhibits TF-dependent **FX** activation
SO Thrombosis Research (**1997**), 86(1), 57-67
CODEN: THBRAA; ISSN: 0049-3848
AB The authors have found that synthetic peptides derived from the two epidermal growth factor-like domains of **factor VII** are inhibitors of tissue factor dependent factor X activation. Inhibition was most pronounced for a constrained sequence of amino acids corresponding to positions 91-102 of **factor VII**, Cys-Val-Asn-Glu-Asn-Gly-Gly-Cys-Glu-Gln-Tyr-Cys. The biol. activity appeared to be localized to the tripeptide "motif", Glu-Gln-Tyr, within the larger sequence. The cyclic peptide was also an inhibitor of tissue factor induced coagulation of plasma, using lipidated tissue factor or tissue factor expressed on the surface of living cells. However, it did not interfere with intrinsic coagulation. Inhibition of factor X activation was dose-dependent with an IC50 value of 350 .mu.M. Kinetic analyses revealed non-competitive inhibition with respect to factor X and suggested that the peptide sequence interferes with the **factor VII**/tissue factor/factor X complex formation and function. A pentapeptide analog of the putative pharmacophore was also a dose-dependent inhibitor of factor X activation with an IC50 value of 560 .mu.M, but the tripeptide, Glu-Gln-Tyr, alone was without effect. The authors' results suggest a direct role for the second epidermal growth factor-like domain of

factor VII, and in particular its loop I, in the formation and function of the **factor VII** / tissue factor / factor X complex.

L13 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2003 ACS
PY 1995
1995
1998
1995
1996
1998
1996
1996
1997
1998
1995
1996
1999

PATENT NO.	KIND	DATE	
PI WO 9500541	A1	19950105	<--
AU 9469755	A1	19950117	<--
AU 691814	B2	19980528	
ZA 9404337	A	19950227	<--
EP 703923	A1	19960403	<--
EP 703923	B1	19981007	
CN 1125450	A	19960626	<--
JP 08511794	T2	19961210	<--
HU 74873	A2	19970228	<--
AT 171950	E	19981015	<--
NO 9505067	A	19951214	<--
FI 9506055	A	19960126	<--
US 5962418	A	19991005	<--

IN Stephens, Ross Wentworth; Orning, Lars; Sakariassen, Kjell Steinar
TI Preparation of **factor VII**-derived peptides
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
AB Peptides comprising the amino acid sequences of the formula (IA): CVNENGGCEQYCSD, (IB): FCLPAFEGRNCE and/or (IC): RCHEGYSLLADGVSCT as well as peptide fragments thereof, esters, amides, salts and cyclic derivs. thereof, functional analogs thereof,and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments are prep. These peptides are for use in the prevention or inhibition of binding of tissue factor (TF) to the serine protease factor (FVIIa) or its inactive pro-enzyme **factor VII** (**FVII**) and in turn, limit the formation of the **FVII**/TF and the FVIIa/TF complex, which enhance the activation of **factor VII** to FVIIa and catalyze the conversion of factor X to its active form Xa in the blood clotting process, resp., and thereby are useful for reducing blood clot formation. WISYSDGD, YSDGDQC, and CVNENGGCEQYC, which were prepd. by the solid phase method, at 0.5 mM in vitro inhibited 57, 55, and 78%, resp., the FVIIa/TF complex-mediated activation of factor X to factor Xa.

L13 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2003 ACS
PY 1995
1995
1995

PATENT NO.	KIND	DATE	
PI WO 9500847	A1	19950105	<--

AU 9469754 A1 19950117 <--
ZA 9404336 A 19950227 <--
IN Stephens, Ross Wentworth; Oerning, Lars; Sakariassen, Kjell
TI Immunoassay
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
AB The present invention relates to an assay for the formation of multi-protein complexes (e.g., **factor VII**-tissue factor complex) in, e.g., body fluids by the steps of: (1) reacting a first protein of a multi-protein complex with an immobilized first antibody specific therefor which does not interfere with complex formation; (2) optionally adding further proteins which form part of the multi-protein complex; (3) optionally adding a test substance; (4) adding the remaining protein(s) required for formation of the multi-protein complex; (5) adding a labeled second antibody specific to a protein added in step (4); and (6) detecting and optionally detg. the amt. of the second antibody immobilized as an indication of multi-protein complex formation. Such an assay can be used to det. whether or to what degree a naturally produced multi-protein complex is formed by an individual. In this way any malfunction in formation of a multi-protein complex, for example due to a genetic disorder or physiol. disturbance can be ascertained. Examples are given of the detn. of the multi-protein complex **factor VII**-tissue factor by ELISA and use of this assay to analyze human blood plasma.

L13 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2003 ACS
PY 1994
1994
1994
1995

PATENT NO.	KIND	DATE	
PI WO 9409034	A1	19940428	<--
ZA 9307553	A	19940503	<--
AU 9351458	A1	19940509	<--
EP 668875	A1	19950830	<--

IN Eisenberg, Paul; Rylatt, Dennis Brian; Hillyard, Carmel Judith; Bundesen, Peter Gregory
TI Directing anticoagulants to blood clots using conjugates with ligands for clot proteins and their preparation and use
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
AB Anticoagulants are directed to clots by conjugating them with ligands for clot proteins such as an antibody to fibrin. The clot-targeting, anticoagulant mol. may also include a thrombolytic coupled to the clot-targeting binding mol. or a thrombolytic coupled to the anticoagulant. Conjugates of the Fab-SH fragment of anti-thrombin antibody DD-3B6/22 and the anticoagulant peptide PPACK were prepd. by std. methods. The conjugate was able to bind thrombin and the D-dimer and to inhibit thrombin action in a dose-dependent manner. The chem. synthesis of conjugates of the antibody and hirudin analogs and the cloning of genes for antibody fragments for prepn. of conjugates by expression of cloned genes for fusion proteins are described.

L13 ANSWER 5 OF 13 USPATFULL
PI US 6121435 20000919 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium

LaRoche, Yves Rene, Brusselles, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CO, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 6 OF 13 USPATFULL
PI US 6096877 20000801 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Brussels, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CO, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 7 OF 13 USPATFULL
PI US 6090916 20000718 <--
WO 9612021 19960425 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Brussels, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CO, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 8 OF 13 USPATFULL
PI US 6087487 20000711 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Brussels, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium

Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CA, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 9 OF 13 USPATFULL
PI US 6046318 20000404 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Bruxelles, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CO, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 10 OF 13 USPATFULL
PI US 6040441 20000321 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Dilbeek, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Brussels, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Boulder, CO, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 11 OF 13 USPATFULL
PI US 5962418 19991005 <--
WO 9500541 19950105
IN Sakariassen, Kjell Steinar, Oslo, Norway
Stephens, Ross Wentworth, Copenhagen, Denmark
Orning, Lars, Oslo, Norway
TI **Factor VII**-derived peptides
AB The present invention relates to compounds comprising the amino acid sequences of the formulae (IA): -CVNENGGCEQYCSD-, (IB): -FCLPAFEGRNCE- and/or (IC): -RCHEGYSLLADGVSCT- as well as peptide fragments thereof, esters, amides, salts and cyclic derivatives thereof, functional

analogues thereof and extended peptide chains carrying amino acids or peptides at the termini of the above sequences or fragments, for use in the prevention or inhibition of binding of tissue factor to **FVII**

L13 ANSWER 12 OF 13 USPATFULL
PI US 5955294 19990921 <--
IN Vlasuk, George Phillip, Carlsbad, CA, United States
Stanssens, Patrick Eric Hugo, St-Martens-Latem, Belgium
Messens, Joris Hilda Lieven, Antwerp, Belgium
Lauwereys, Marc Josef, Haaltert, Belgium
LaRoche, Yves Rene, Brussels, Belgium
Jespers, Laurent Stephane, Tervuren, Belgium
Gansemans, Yannick Georges Jozef, Ichtegem, Belgium
Moyle, Matthew, Escondido, CA, United States
Bergum, Peter W., San Diego, CA, United States
TI Nematode-extracted serine protease inhibitors and anticoagulant proteins
AB Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

L13 ANSWER 13 OF 13 USPATFULL
PI US 5891664 19990406 <--
IN Dan.o slashed. , Keld, Charlottenlund, Denmark
Blasi, Francesco, Charlottenlund, Denmark
Roldan, Ann Louring, Vallensb.ae butted.k, Denmark
Cubellis, Maria Vittoria, Napoli, Italy
Masucci, Maria Teresa, Napoli, Italy
Appella, Ettore, Chevy Chase, MD, United States
Schleuning, Wolf-Dieter, Berlin, Germany, Federal Republic of
Behrendt, Niels, Bagsv.ae butted.rd, Denmark
R.o slashed.nne, Ebbe, Copenhagen, Denmark
Kristensen, Peter, Copenhagen, Denmark
Pollanen, Jari, Espoo, Finland
Salonen, Eeva-Marjatta, Espoo, Finland
Stephens, Ross W., Helsinki, Finland
Tapiovaara, Hannele, Helsinki, Finland
Vaheri, Antti, Kauniainen, Finland
M.o slashed.ller, Lisbeth Birk, Bagsv.ae butted.rd, Denmark
Ellis, Vincent, Copenhagen, Denmark
Lund, Leif R.o slashed.ge, Copenhagen, Denmark
Ploug, Michael, Copenhagen, Denmark
Pyke, Charles, S.o slashed.borg, Denmark
Patthy, Laszlo, Budapest, Hungary
TI Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
AB Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

=> d hist

09921880

```
     (FILE 'HOME' ENTERED AT 11:06:25 ON 30 JAN 2003)

     FILE 'REGISTRY' ENTERED AT 11:06:52 ON 30 JAN 2003
L1       168545 S C.....C/SQSP
L2        60610 S L1 AND SQL<=210

     FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,
     USPAT2, EUROPATFULL' ENTERED AT 11:29:46 ON 30 JAN 2003

     FILE 'REGISTRY' ENTERED AT 11:32:16 ON 30 JAN 2003
L3           14 S CWTWETC/SQSP

     FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,
     USPAT2, EUROPATFULL' ENTERED AT 11:33:06 ON 30 JAN 2003
L4            3 S L3

     FILE 'REGISTRY' ENTERED AT 11:35:06 ON 30 JAN 2003
L5         4615 S L1 AND SQL<=20
L6         1711 S L1 AND SQL<=10

     FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, SCISEARCH, PCTFULL, USPATFULL,
     USPAT2, EUROPATFULL' ENTERED AT 11:36:13 ON 30 JAN 2003
L7         2997 S L5
L8          752 S L7 AND (FACTOR OR THROMBOSIS)
L9           18 S L7 AND (FACTOR (W) VII)
L10          18 DUP REM L9 (0 DUPLICATES REMOVED)
L11         530 S L7 AND ((FACTOR (W) VII) OR FVII OR FX OR X)
L12          19 S L7 AND ((FACTOR (W) VII) OR FVII OR FX)
L13          13 S L12 AND PY<=2000
```